Although these variants do not have a strong and consistent association with susceptibility to liver fibrosis progression in all populations, they emphasize the critical role of IL-17 in perpetuating chronic inflammation and fibrogenesis in MASLD. The gene discussed is IL17A; the disease is metabolic dysfunction-associated steatotic liver disease.